Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
6,540 results
  • Hybrid Silica-Coated PLGA Nanoparticles for Enhanced Enzyme-Based Therapeutics. [Journal Article]
    Pharmaceutics. 2022 Dec 31; 15(1)Gustafson KT, Mokhtari N, … Fischer JM
  • Some cancer cells rely heavily on non-essential biomolecules for survival, growth, and proliferation. Enzyme based therapeutics can eliminate these biomolecules, thus specifically targeting neoplastic cells; however, enzyme therapeutics are susceptible to immune clearance, exhibit short half-lives, and require frequent administration. Encapsulation of therapeutic cargo within biocompatible and bi…
  • A rational approach for 3D recognition and removal of L-asparagine via molecularly imprinted membranes. [Journal Article]
    J Pharm Biomed Anal. 2023 Jan 14; 226:115250.Acet Ö, Ali Noma SA, … Odabaşı M
  • In this study, a L-asparagine (L-Asn) imprinted membranes (L-Asn-MIPs) were synthesized via molecular imprinting for selective and efficient removal of L-Asn. The L-Asn-MIP membrane was prepared by using acrylamide (AAm) and hydroxyethyl methacrylate (HEMA) as a functional monomer and a comonomer, respectively. The membrane was characterized by scanning electron microscopy (SEM) and Fourier Trans…
  • Drugs and Lactation Database (LactMed): Pegaspargase [BOOK]
    Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
  • No information is available on the clinical use of pegaspargase during breastfeeding. . Because pegaspargase is a large protein molecule with a molecular weight of about 140,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, the manufacturer recommends that the drug not be used during bre…
  • Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. [Review]
    Front Immunol. 2022; 13:955476.Pal S, Sharma A, … Jaganathan BG
  • Cancer is a heterogeneous disease characterized by various genetic and phenotypic aberrations. Cancer cells undergo genetic modifications that promote their proliferation, survival, and dissemination as the disease progresses. The unabated proliferation of cancer cells incurs an enormous energy demand that is supplied by metabolic reprogramming. Cancer cells undergo metabolic alterations to provi…
  • Top advances of the year: Leukemia. [Journal Article]
    Cancer. 2022 Dec 30 [Online ahead of print]Kent A, Pollyea DA
  • In the year 2021, there were three new Food and Drug Administration approvals for all leukemia types: asciminib (Scemblix) for chronic myeloid leukemia, brexucabtagene autoleucel (Tecartus) for relapsed/refractory B-cell acute lymphocytic leukemia, and asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) for acute lymphocytic leukemia. This is down from 2017-2018 when eight new therapies…
  • A scoping review to compare and contrast quality assurance aspects of l-asparaginase biosimilars. [Review]
    Int J Pharm. 2022 Dec 26; 632:122523.Qin X, Costa-Silva TA, … Long PF
  • l-asparaginase is a first-line medicine used for the treatment of acute lymphoblastic leukemia. Differing quality of marketed l-asparaginase biosimilars has been reported to adversely influence treatment outcomes. Herein, the quality of l-asparaginase biosimilars intended for clinical use was reviewed in sight of quality assurance parameters using English and Chinese language database searching, …
  • Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine. [Journal Article]
    Front Oncol. 2022; 12:1035537.Bollino D, Claiborne JP, … Emadi A
  • The impact of asparaginases on plasma asparagine and glutamine is well established. However, the effect of asparaginases, particularly those derived from Erwinia chrysanthemi (also called crisantaspase), on circulating levels of other amino acids is unknown. We examined comprehensive plasma amino acid panel measurements in healthy immunodeficient/immunocompetent mice as well as in preclinical mou…
  • ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner. [Journal Article]
    Dig Liver Dis. 2022 Dec 24 [Online ahead of print]Wang X, Wang Y, … Tao K
  • The asparaginase-like protein 1 (ASRGL1) catalyzes the hydrolysis of L-asparagine to L-aspartic acid and ammonia. Emerging evidences have shown a strong correlation between ASRGL1 expression and tumorigenesis. However, the expression and biological function of ASRGL1 in hepatocellular carcinoma (HCC) are still unclear. Here, we explored anti-tumor activity and fundamental mechanisms of ASRGL1 blo…
  • Enhancing CHO cell productivity through a dual selection system using Aspg and Gs in glutamine free medium. [Journal Article]
    Biotechnol Bioeng. 2022 Dec 23 [Online ahead of print]Ha TK, Òdena A, … Lewis NE
  • The dominant method for generating Chinese hamster ovary (CHO) cell lines that produce high titers of biotherapeutic proteins utilizes selectable markers such as dihydrofolate reductase (Dhfr) or glutamine synthetase (Gs), alongside inhibitory compounds like methotrexate or methionine sulfoximine, respectively. Recent work has shown the importance of asparaginase (Aspg) for growth in media lackin…
  • Elucidation of the Reaction Mechanism of Cavia porcellus l-Asparaginase: A QM/MM Study. [Journal Article]
    J Chem Inf Model. 2023 Jan 09; 63(1):270-280.Sánchez L, Medina FE, … Jaña GA
  • The l-asparaginase (l-ASNase) enzyme catalyzes the conversion of the non-essential amino acid l-asparagine into l-aspartic acid and ammonia. Importantly, the l-ASNases are used as a key part of the treatment of acute lymphoblastic leukemia (ALL); however, despite their benefits, they trigger severe side effects because they have their origin in bacterial species (Escherichia coli and Erwinia chry…
New Search Next